Cutler Group’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-18,900
| Closed | -$7K | – | 5646 |
|
|
2022
Q3 | $7K | Buy |
18,900
+3,500
| +23% | +$145K | ﹤0.01% | 3446 |
|
|
2022
Q2 | $189K | Sell |
15,400
-31,400
| -67% | -$692K | 0.01% | 1045 |
|
|
2022
Q1 | $392K | Buy |
46,800
+25,000
| +115% | +$703K | 0.02% | 781 |
|
|
2021
Q4 | $166K | Sell |
21,800
-9,200
| -30% | -$323K | 0.01% | 1472 |
|
|
2021
Q3 | $315K | Sell |
31,000
-77,900
| -72% | -$1.21M | 0.01% | 1060 |
|
|
2021
Q2 | $960K | Buy |
108,900
+95,900
| +738% | +$2.36M | 0.04% | 467 |
|
|
2021
Q1 | $91K | Buy |
13,000
+12,400
| +2,067% | +$746K | ﹤0.01% | 1854 |
|
|
2020
Q4 | $1K | Sell |
600
-14,800
| -96% | -$847K | ﹤0.01% | 4677 |
|
|
2020
Q3 | $40K | Buy |
15,400
+14,500
| +1,611% | +$781K | ﹤0.01% | 1950 |
|
|
2020
Q2 | $1K | Sell |
900
-3,800
| -81% | -$207K | ﹤0.01% | 4241 |
|
|
2020
Q1 | $36K | Buy |
+4,700
| New | +$200K | ﹤0.01% | 1935 |
|
|
2018
Q1 | – | Sell |
-2,000
| Closed | -$1K | – | 5503 |
|
|
2017
Q4 | $1K | Buy |
+2,000
| New | +$13.7K | ﹤0.01% | 4663 |
|
|
2017
Q2 | – | Sell |
-3,500
| Closed | -$2K | – | 7339 |
|
|
2017
Q1 | $2K | Sell |
3,500
-1,500
| -30% | -$10.8K | ﹤0.01% | 5622 |
|
|
2016
Q4 | $8K | Buy |
+5,000
| New | +$36K | ﹤0.01% | 4510 |
|
|
2016
Q1 | – | Sell |
-700
| Closed | -$1K | – | 7423 |
|
|
2015
Q4 | $1K | Buy |
+700
| New | +$4.95K | ﹤0.01% | 6168 |
|
Other funds holding CCXI
Cutler Group's CCXI Position: Q4 2022 in Review
Cutler Group sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 8,000 shares — an estimated $413K sold.
Cutler Group first reported a position in CCXI in Q4 2015 and held it in 23 quarters. The position peaked at $635K in Q1 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Cutler Group reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Cutler Group sold 8,000 ChemoCentryx, Inc. shares in Q4 2022, an estimated $413K.
- Cutler Group first reported a position in ChemoCentryx, Inc. in Q4 2015 and held it in 23 quarters.
- Cutler Group's ChemoCentryx, Inc. position peaked at $635K in Q1 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.